https://theweightlossatlas.com/companies/lilly/Eli Lilly weight-loss and diabetes news from the Weight Loss Atlas: trial results, approvals, earnings call takeaways and what is coming next. Company statements are labeled as such.en-usFri, 30 Oct 2026 12:00:00 GMT https://theweightlossatlas.com/news/medicare-bridge-uptake/atlas-news-medicare-bridge-uptakeThu, 29 Oct 2026 12:00:00 GMTCoverageOn its third-quarter 2026 earnings call on October 29, 2026, Eli Lilly said more than half a million people have filled a prescription for a Lilly medicine through the Medicare GLP-1 Bridge since the program began on July 1. The figure counts people, not prescriptions, and covers Lilly medicines only. Lilly also said about 75% of people entering the Bridge go on to an injectable, and that it wants the program moved into the Part D benefit, with carrier work for calendar year 2028. These are company statements, not independent data. https://theweightlossatlas.com/news/retatrutide-transcend-t2d2/atlas-news-retatrutide-transcend-t2d2Wed, 28 Oct 2026 12:00:00 GMTTrial resultsEli Lilly announced top-line results from TRANSCEND-T2D-2, a phase 3 trial that compared once-weekly retatrutide with Ozempic (semaglutide) 2 mg, the highest approved dose, in 1,298 adults with type 2 diabetes who were still above target on metformin. It was open label, meaning everyone knew which medicine they were taking. At 80 weeks, A1C, a measure of average blood sugar, fell by 2.2 percentage points on both retatrutide doses (9 mg and 12 mg) and by 1.8 on Ozempic, from an average of 8.3%. Average weight fell by 19.5% on 9 mg and 20.9% on 12 mg, versus 9.4% on Ozempic. Stopping because of side effects was 4.8% on 9 mg and 7.9% on 12 mg, versus 2.7% on Ozempic. Diarrhea, nausea, constipation and vomiting were the most common side effects. Abnormal skin sensations (dysesthesia) were reported by 4.8% and 6.5% on retatrutide versus 2.7% on Ozempic. Worth knowing: These figures come from a Lilly announcement, not a journal paper, and they count people while they stayed on treatment. Lilly paid for the trial. It was done in people with type 2 diabetes, so it does not show how retatrutide compares with semaglutide for weight loss in people without diabetes. Lilly says full results will be presented at a medical meeting and published. Retatrutide is not approved for any use. https://theweightlossatlas.com/news/retatrutide-sleep-apnea/atlas-news-retatrutide-sleep-apneaTue, 20 Oct 2026 12:00:00 GMTTrial resultsThe New England Journal of Medicine published two placebo-controlled trials of once-weekly retatrutide in adults with moderate-to-severe obstructive sleep apnea and a body mass index of at least 27. TRIUMPH-1-OSA had 243 people without type 2 diabetes. TRIUMPH-2-OSA had 448 people with type 2 diabetes. At 80 weeks, the average number of breathing interruptions per hour of sleep (the AHI) fell by 9.9 on placebo in the first trial and by 22.9, 34.3 and 31.7 on the 4 mg, 9 mg and 12 mg doses. In the second trial it fell by 10.3 on placebo and by 19.2, 24.7 and 25.4. Average weight loss was 12.5% to 22.2% in the first trial and 12.1% to 18.5% in the second, versus 4.8% and 5.6% on placebo. The most common side effects were stomach and gut problems. Worth knowing: The AHI counts breathing events. The abstract does not say how many people no longer had sleep apnea afterward. Lilly paid for the trials, and retatrutide is not approved for any use. Lilly has said it plans to file with the FDA in the first quarter of 2027. https://theweightlossatlas.com/news/retatrutide-triumph1/atlas-news-retatrutide-triumph1Tue, 29 Sep 2026 12:00:00 GMTTrial resultsEli Lilly's once-weekly retatrutide was compared with placebo for 80 weeks in 2,339 adults with obesity and no diabetes (TRIUMPH-1). Average weight change was -17.6% at 4 mg, -23.7% at 9 mg and -25.0% at 12 mg, versus -3.9% on placebo. In the 574 people with knee osteoarthritis, pain scores improved by about 1.6 to 1.8 points more than placebo in the trial's main analysis, on a 1 to 10 scale where higher means worse pain. In the 243 people with obstructive sleep apnea, apnea events per hour fell by about 22 to 25 more than placebo. The most common side effects were stomach and gut problems. Worth knowing: Lilly paid for the trial. The Atlas read the journal abstract, not the full paper. Retatrutide is not approved for any use, and Lilly has said it plans to file with the FDA in the first quarter of 2027. https://theweightlossatlas.com/news/retatrutide-triumph/atlas-news-retatrutide-triumphThu, 23 Jul 2026 12:00:00 GMTTrial resultsLilly announced results from TRIUMPH-2 (people with type 2 diabetes) and TRIUMPH-3 (severe obesity with cardiovascular disease). At 80 weeks, average weight loss was up to 20.8% in TRIUMPH-2 and up to 22.6% in TRIUMPH-3, versus 4.0% and 3.2% on placebo. Stopping because of side effects was 3.8% to 13.5% on retatrutide versus 4.8% to 4.9% on placebo. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. Worth knowing: These are company-announced results. Retatrutide is investigational and not approved or available as a medicine anywhere. https://theweightlossatlas.com/news/foundayo-approved/atlas-news-foundayo-approvedWed, 01 Apr 2026 12:00:00 GMTApprovalThe FDA approved orforglipron as Foundayo for adults with obesity, or overweight with a related condition. It is a daily tablet taken with or without food. In the 72-week ATTAIN-1 trial, people on the highest dose who stayed on treatment lost an average of 12.4% of body weight, versus 0.9% on placebo. Across everyone randomized, the figures were 11.1% versus 2.1%. Lilly said self-pay prices start at $149 a month for the lowest dose, with other prices depending on insurance. Worth knowing: Prices and coverage change often. The label lists the warnings, including pancreatitis, gallbladder problems and dehydration. https://theweightlossatlas.com/news/medicare-bridge/atlas-news-medicare-bridgeWed, 06 May 2026 12:00:00 GMTCoverageNPR reported a temporary Medicare program running from July 1, 2026 through December 31, 2027. People in a Part D plan who meet the criteria can get Wegovy, the Zepbound KwikPen or Foundayo for a flat $50 a month. The criteria are a BMI of 35 or higher, or 27 or higher with a condition such as heart disease or prediabetes, and prior authorization is required. Worth knowing: Rules like this change. Check Medicare.gov and your own plan. The Medicare page has the details.